The 44.8% ORR in late-line CRC is strong for a Phase 1 ADC and supports further development. Watch for Phase 1b dose optimization data in 2027 and any partnership or licensing activity around the ADC platform.
Price Chart
Executive Summary
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted ADC ARR-217 at ESMO 2026, showing a 44.8% ORR at the 6 mg/kg dose in heavily pretreated colorectal cancer patients. The drug was generally well-tolerated with no Grade 5 TRAEs or ILD, and the program has advanced into Phase 1b dose optimization with data expected in 2027.
Key Facts
- Phase 1 data for ARR-217 (MRG007) presented at ESMO Congress 2026
- At 6 mg/kg Q3W dose: 44.8% ORR (13/29) in pre-treated CRC patients
- At 6 mg/kg Q3W dose: 93.1% DCR (27/29) in pre-treated CRC patients
- At doses ≥4 mg/kg Q3W: 34.2% ORR (25/73) in CRC patients
- At doses ≥4 mg/kg Q3W: 91.8% DCR in CRC patients
- 123 patients treated across 6 dose levels (2-8 mg/kg); 113 with CRC
- 30.1% (37/123) Grade ≥3 TRAEs across all doses; at 6 mg/kg: 20.4% (10/49)
- No Grade 5 TRAEs or ILD observed
- ARR-217 advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W
- Dose optimization data expected in 2027
Financial Impact
No financial data in filing; clinical-stage company with no approved products or reported revenue
Risk Factors
- Phase 1 data is early-stage; ORR may not replicate in larger randomized trials
- 30.1% Grade ≥3 TRAE rate across all doses warrants monitoring in dose optimization
- No cross-filing context provided; no prior financial or pipeline data available for comparison
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-118550 |
| Document: tm2628237d1_ex99-1.htm | 0001104659-26-118550 |
| Document: 0001104659-26-118550-index-headers.html | 0001104659-26-118550 |
| Document: 0001104659-26-118550-index.html | 0001104659-26-118550 |
| Document: 0001104659-26-118550.txt | 0001104659-26-118550 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 25, 2026 2d ago | Press Release | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 23, 2026 4d ago | Press Release | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 19, 2026 8d ago | 8-K | $17.94 $18.85 | ▲ +5.07% | ▲ +4.74% | $15.40 (−14.16%) |
Oct 13, 2026 14d ago | SC 13G | $16.20 $16.79 | ▲ +3.64% | ▲ +3.36% | $15.40 (−4.94%) |
Oct 13, 2026 14d ago | 8-K | $16.09 $16.20 | ▲ +0.68% | ▲ +1.76% | $15.40 (−4.29%) |
Oct 8, 2026 18d ago | SC 13D/A | $16.73 $16.46 | ▲ +1.61% | ▲ +1.55% | $15.40 (+7.95%) |
Oct 6, 2026 21d ago | 8-K | $15.09 $16.89 | ▼ −11.93% | ▼ −12.17% | $15.40 (−2.05%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.51 | ▲ +1.63% | ▲ +1.44% | $15.40 (+48.67%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $30.30 | ▼ −0.79% | ▼ −2.55% | $15.40 (−49.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers